Compare Peptides, Head-to-Head
Cross-shopping two peptides? These neutral, research-first comparisons break down how popular peptides differ in mechanism, evidence, approval status, and safety.
Cross-shopping two peptides? These neutral, research-first comparisons break down how popular peptides differ in mechanism, evidence, approval status, and safety.
Semaglutide (Ozempic, Wegovy) vs tirzepatide (Mounjaro, Zepbound): how the two weight-loss drugs differ in mechanism, trial weight loss, and side effects.
Compare →Tirzepatide (Mounjaro) vs retatrutide: dual vs triple incretin agonist, trial weight loss, and approval status compared.
Compare →Semaglutide (Ozempic, Wegovy) vs liraglutide (Victoza, Saxenda): weekly vs daily GLP-1, weight-loss results, and dosing compared.
Compare →Semaglutide (Ozempic, Wegovy) vs retatrutide: single GLP-1 vs triple agonist, weight-loss data, and approval status.
Compare →BPC-157 vs TB-500: how the two popular 'healing' research peptides differ in origin, mechanism, and evidence — and what they share.
Compare →Ipamorelin vs CJC-1295: GHRP vs GHRH analog, how they differ, and why they're often combined for growth-hormone release.
Compare →Ipamorelin vs sermorelin: GHRP vs GHRH analog for growth-hormone release, mechanism and status compared.
Compare →Sermorelin vs CJC-1295: two GHRH analogs compared — half-life, the DAC difference, and regulatory status.
Compare →GHRP-6 vs ipamorelin: two growth-hormone-releasing peptides compared — appetite, selectivity, and side effects.
Compare →Afamelanotide (Melanotan I, Scenesse) vs Melanotan II: an FDA-approved implant vs an unapproved tanning peptide.
Compare →Semaglutide (Ozempic) vs dulaglutide (Trulicity): two once-weekly GLP-1 drugs compared on weight loss, dosing convenience, and cardiovascular evidence.
Compare →Dulaglutide (Trulicity) vs tirzepatide (Mounjaro): single GLP-1 vs dual GIP/GLP-1 agonist compared on weight loss, A1c, and dosing.
Compare →Tirzepatide (Mounjaro) vs liraglutide (Victoza, Saxenda): weekly dual agonist vs daily GLP-1, compared on weight loss and dosing.
Compare →Liraglutide (Victoza, Saxenda) vs dulaglutide (Trulicity): daily vs weekly GLP-1 agonists compared on dosing, weight loss, and use.
Compare →Semaglutide (Ozempic) vs exenatide (Byetta, Bydureon): the newer GLP-1 vs the first-generation agent, compared on potency and dosing.
Compare →Cagrilintide vs semaglutide: a long-acting amylin analog vs a GLP-1 agonist — different hunger pathways, and why they're combined as CagriSema.
Compare →Survodutide vs retatrutide: a glucagon/GLP-1 dual agonist vs a GIP/GLP-1/glucagon triple agonist — two investigational next-gen obesity drugs compared.
Compare →Mazdutide vs retatrutide: a GLP-1/glucagon dual agonist vs a GIP/GLP-1/glucagon triple agonist — two investigational obesity drugs compared.
Compare →Tirzepatide (Mounjaro) vs survodutide: an approved GIP/GLP-1 dual agonist vs an investigational glucagon/GLP-1 dual agonist.
Compare →GHRP-2 vs GHRP-6: two growth-hormone-releasing peptides compared on potency, appetite stimulation, and side effects.
Compare →CJC-1295 vs tesamorelin: two GHRH analogs compared — an unapproved research peptide vs an FDA-approved drug for HIV-related fat.
Compare →Tesamorelin vs sermorelin: two GHRH analogs compared — an FDA-approved visceral-fat drug vs a formerly-approved, now-compounded peptide.
Compare →Hexarelin vs ipamorelin: two growth-hormone-releasing peptides compared on potency, selectivity, tolerance, and side effects.
Compare →IGF-1 LR3 vs MGF (mechano growth factor): two IGF-pathway research peptides compared on mechanism and how they're studied for muscle.
Compare →TB-500 vs Thymosin Beta-4: how the popular research peptide relates to the natural protein it's derived from — and why they're not identical.
Compare →BPC-157 vs GHK-Cu: an injected 'healing' research peptide vs a topical copper skin peptide — different uses, routes, and evidence.
Compare →GHK-Cu vs Argireline: two cosmetic skincare peptides compared — copper-peptide collagen support vs 'Botox-like' expression-line smoothing.
Compare →Semax vs Selank: two Russian nootropic peptides compared — focus and neuroprotection vs calm and anti-anxiety effects.
Compare →Noopept vs Semax: an orally-active racetam-like compound vs an intranasal peptide — two nootropics compared on form and evidence.
Compare →Leuprolide (Lupron) vs cetrorelix (Cetrotide): GnRH agonist vs antagonist — why one suppresses hormones after a flare and the other blocks immediately.
Compare →PT-141 (bremelanotide, Vyleesi) vs Melanotan II: two melanocortin peptides compared — an FDA-approved libido drug vs an unapproved tanning chemical.
Compare →Teriparatide (Forteo) vs abaloparatide (Tymlos): two FDA-approved bone-building osteoporosis drugs compared on mechanism and use.
Compare →Linaclotide (Linzess) vs plecanatide (Trulance): two FDA-approved guanylate cyclase-C agonists for constipation and IBS-C compared.
Compare →Goserelin (Zoladex) vs leuprolide (Lupron): two FDA-approved GnRH agonists compared on formulation and use in cancer and gynecology.
Compare →Cetrorelix (Cetrotide) vs degarelix (Firmagon): two FDA-approved GnRH antagonists compared — IVF use vs prostate cancer.
Compare →GHRP-6 vs CJC-1295: a growth-hormone-releasing peptide vs a GHRH analog — different receptors, and why they're stacked.
Compare →GHRP-2 vs ipamorelin: two growth-hormone-releasing peptides compared on potency, selectivity, and side effects.
Compare →Tesamorelin vs ipamorelin: an FDA-approved GHRH analog vs an unapproved selective GHRP — different classes, regulatory status, and use.
Compare →MOTS-c vs humanin: two mitochondrial-derived peptides compared — metabolic/exercise-mimetic vs cytoprotective and neuroprotective research.
Compare →Thymosin Alpha-1 vs Thymalin: two thymic immune peptides compared — a defined single peptide (Zadaxin) vs a thymic peptide preparation.
Compare →Argireline vs SNAP-8: two SNARE-targeting cosmetic peptides compared — the original 'topical Botox' hexapeptide vs its extended octapeptide.
Compare →Matrixyl vs Argireline: two cosmetic peptides compared — collagen-stimulating matrikine vs SNARE-targeting expression-line smoother.
Compare →Pramlintide (Symlin) vs cagrilintide: two amylin analogs compared — an approved mealtime injection vs an investigational long-acting obesity drug.
Compare →Follistatin vs ACE-031: two myostatin-pathway research compounds compared — a myostatin-binding protein vs a soluble activin receptor decoy.
Compare →Insulin vs semaglutide (Ozempic): two injectable diabetes treatments that work very differently — including opposite effects on body weight.
Compare →Gonadorelin vs leuprolide (Lupron): why pulsatile GnRH stimulates sex hormones while continuous GnRH-agonist dosing suppresses them.
Compare →Kisspeptin vs gonadorelin: the reproductive 'master switch' upstream of GnRH, compared with GnRH itself.
Compare →Tirzepatide (Mounjaro) vs mazdutide: a GIP/GLP-1 dual agonist vs a GLP-1/glucagon dual agonist — different second receptors, different maturity.
Compare →Tesamorelin vs AOD-9604: an FDA-approved drug for visceral fat vs an unapproved 'fat-loss' research peptide derived from growth hormone.
Compare →SS-31 (elamipretide) vs MOTS-c: two mitochondria-focused peptides compared — a membrane-targeting drug candidate vs a mitochondrial-derived signaling peptide.
Compare →BPC-157 vs ipamorelin: a 'healing' research peptide vs a growth-hormone secretagogue — different mechanisms, often stacked, both unapproved.
Compare →Semax vs Cerebrolysin: a defined nootropic peptide vs a complex brain-derived neuropeptide mixture — both used in Russia, neither FDA-approved.
Compare →Liraglutide (Victoza, Saxenda) vs exenatide (Byetta, Bydureon): two early GLP-1 receptor agonists compared on dosing and origin.
Compare →Teriparatide (Forteo) vs calcitonin: an anabolic bone-building osteoporosis drug vs an antiresorptive that slows bone loss.
Compare →GHK-Cu vs Matrixyl: two collagen-focused cosmetic peptides compared — a copper tripeptide vs a matrikine — and why they're often combined.
Compare →Thymosin Alpha-1 vs LL-37: a thymic immune-modulating peptide vs a natural antimicrobial peptide — two very different immune roles.
Compare →Octreotide (Sandostatin) vs lanreotide (Somatuline): how the two long-acting somatostatin analogs differ in receptor binding, formulation, approved uses,…
Compare →Octreotide vs pasireotide: how the older and newer somatostatin analogs differ in receptor binding, why pasireotide works in Cushing's disease, and its…
Compare →Desmopressin vs vasopressin: how the engineered analog differs from the natural antidiuretic hormone in receptor selectivity, uses, and why only one raises…
Compare →HGH Fragment 176-191 vs AOD-9604: how the two growth-hormone fat-loss fragments relate, what the animal and human evidence shows, and why neither is proven.
Compare →IGF-1 DES vs IGF-1 LR3: how the two modified insulin-like growth factor analogs differ in structure, potency, and duration — and why neither has human…
Compare →Semaglutide vs mazdutide: how the approved GLP-1 drug compares with the investigational GLP-1/glucagon dual agonist in mechanism, evidence, and approval status.
Compare →